“`html
Phase II Study Summary
A clinical trial was conducted to evaluate the effectiveness and safety of using a specific chemotherapy and radiotherapy regimen followed by surgery in treating advanced esophageal cancer.
Practical Solutions and Value
- The study enrolled 24 newly diagnosed esophageal cancer patients to assess the treatment approach.
- The treatment involved a specific radiotherapy regimen and chemotherapy protocol.
- The primary endpoints were disease-free survival, overall survival, and evaluation of hematologic toxicity.
- The study population had a median age of 55.5 years, with over 90% of the patients being male.
- The 5-year disease-free survival was 37.1%, and the 5-year overall survival was 48.7%.
- The pathologic complete response rate was 45.8%.
- The most common toxicities were leukopenia and thrombocytopenia, but no severe hematologic toxicity was reported.
- The use of the specific treatment regimen demonstrated tolerable toxicity and achieved acceptable disease-free and overall survival outcomes.
“`
